WSTAM
ARQT icon

Wilbanks Smith & Thomas Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$64.6K – 529
2023
Q4 		$64.6K Buy
+20,000
New +$54.4K ﹤0.01% 515

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ARQT Position: Q1 2024 in Review

Wilbanks Smith & Thomas Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 20,000 shares — an estimated $64.6K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ARQT in Q4 2023 and held it in 1 quarter. The position peaked at $64.6K in Q4 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 20,000 Arcutis Biotherapeutics shares in Q1 2024, an estimated $64.6K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Arcutis Biotherapeutics position peaked at $64.6K in Q4 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.